Malignant pleural effusions: Fixing the leaky faucet

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 1, 2008, Pages 3-5

  Lee, Y C Gary ^a,b   Wilkosz, Sylwia ^c  

^a Oxford Centre for Respiratory Medicine   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; VASCULOTROPIN; ZOLEDRONIC ACID;

ACUTE RESPIRATORY FAILURE; BLOOD VESSEL PERMEABILITY; CANCER INCIDENCE; DYSPNEA; EDITORIAL; HUMAN; INFLAMMATORY CELL; LUNG ADENOCARCINOMA; MESOTHELIOMA; MESOTHELIUM CELL; MORTALITY; NONHUMAN; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOMATOLOGY;

ANIMALS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MICE; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS;

EID: 46349110758     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200804-616ED     Document Type: Editorial

References (16)

1. Davies HE, Lee YCG. Pleurodesis. In: Light RW, Lee YCG, editors. Textbook of pleural diseases, 2nd ed. London: Arnold Press; 2008. pp. 569-582.
2. Lee YCG, Baumann MH, Maskell NA, Waterer GW, Eaton TE, Davies RJO, Heffner JE, Light RW. Pleurodesis practice for malignant pleural effusions in five English speaking countries: survey of pulmonologists. Chest 2003;124:2229-2238.
3. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S. Zhou Z, Papiris SA, Roussos C, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008;178:50-59.
4. Davies HE, Lee YCG, Davies RJO. Pleurodesis for malignant pleural effusion: Talc, toxicity and what next? Thorax (In press)
5. Dresler CM, Olak J, Herndon JE II, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909-915.
6. Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996;62:1655-1658.
7. Maskell NA, Lee YCG, Gleeson FV, Hedley EL, Pengelly G, Davies RJO. Prospective randomized trials comparing the influence of talc of different particle sizes and tetracycline on lung and systemic inflammation after pleurodesis. Am J Respir Crit Care Med 2004;170:377-382.
8. Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F. Loddenkemper R, Herth FJ, Gasparini S, Marquette CH, etal. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007;369:1535-1539.
9. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, et al. Nuclear factor-κB affects tumor progression in a mouse model of malignant pleural effusion. Am .J Respir Cell Mol Biol 2006;34:142-150.
10. Mutsaers SE, Wilkosz S. Structure and function of mesothelial cells. Cancer Treat Res 2007;134:1-19.
11. Grove CS, Lee YCG. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002;8: 294-301.
12. Santini D, Schiavon G, Angeletti S, Vincenzi B, Gasparro S, Grilli C, La Cesa A, Virzi V, Leoni V, Budillon A, et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs? Recent Patents Anticancer Drug Discov 2006;1:383-396.
13. Sandler ED, Hattner RS, Parisi MT, Miller TR. Clinical utility of bone scan features of pleural effusion: sensitivity and specificity for malignancy based on pleural fluid cytopathology. J Nucl Med 1994;35:429-431.
14. Yuasa T. Kimura S, Ashihara E, Habuchi T. Maekawa T. Zoledronic acid: a multiplicity of anti-cancer action. Curr Med Chem 2007;14: 2126-2135.
15. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, Selander KS. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006;12:2862-2868.
16. Hover RJ. Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol 2007;82:409-413.